OncoMatch/Clinical Trials/NCT07223034
A Study of 177Lu-PSMA-617 in People With Gliomas
Is NCT07223034 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Temozolomide and 177Lu-PSMA-617 for glioma.
Treatment: Temozolomide · 177Lu-PSMA-617 — The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Diffuse Intrinsic Pontine Glioma
Biomarker criteria
Required: IDH1 R132H wild-type
IDH1 R132H-wildtype
Required: FOLH1 overexpression (PSMA positive pathological stain (by immunohistochemistry))
PSMA positive pathological stain (by immunohistochemistry) of baseline (pre-radiotherapy) resection or biopsy sample
Excluded: IDH1 non-canonical mutation (i.e., non-R132H)
Patient known to harbor any other non-canonical IDH mutations (i.e., non-R132H)
Allowed: H3F3A (H3 K27M) K27-altered
Diffuse midline glioma, H3 K27-altered
Allowed: H3F3A (H3 K27M) G34-mutant
Diffuse hemispheric glioma, H3 G34-mutant
Allowed: H3F3A (H3 K27M) wild-type
Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype
Allowed: IDH1 wild-type
Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype
Disease stage
Required: Stage GRADE 2, GRADE 3, GRADE 4 (WHO)
WHO grade 2-4 glioma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard of care therapy — including surgery (for resectable tumors) and adjuvant EBRT for glioma
Completion of standard of care therapy including surgery (for resectable tumors) and adjuvant EBRT for glioma
Cannot have received: bevacizumab (bevacizumab)
Receipt of bevacizumab as part of the initial treatment for glioma
Cannot have received: Radium223, Strontium89 or Samarium153 containing compounds (Radium223, Strontium89, Samarium153)
prior exposure to prior Radium223, Strontium89 or Samarium153 containing compounds
Cannot have received: investigational agents
Receipt of any other investigational agents or participation in a concurrent treatment protocol
Cannot have received: radiation therapy
Exception: prior RT to > 25% of the skeleton
prior RT to > 25% of the skeleton
Lab requirements
Blood counts
total white blood count > 3.0 k/mcl; anc ≥ 1.5 k/mcl; platelets ≥ 100 k/mcl; hemoglobin ≥ 9 g/dl
Kidney function
serum creatinine level < 1.5 x uln or egfr > 60 ml/min
Liver function
alt and ast ≤ 2.5 x uln; albumin > 2 g/dl; bilirubin < 3 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify